Publications in collaboration with researchers from Memorial Sloan Kettering Cancer Center (17)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

2023

  1. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  2. Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

    ESMO Open, Vol. 8, Núm. 2

  3. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    ESMO Open, Vol. 8, Núm. 3

2022

  1. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3452-3463

2021

  1. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1496-1510

2020

  1. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

    Cancer discovery, Vol. 10, Núm. 2, pp. 198-213

  2. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

    British Journal of Cancer, Vol. 123, Núm. 11, pp. 1590-1598

2019

  1. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 849-861

  2. Definition of the rectum: An International, expert-based Delphi consensus

    Annals of Surgery, Vol. 270, Núm. 6, pp. 955-959

  3. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors

    Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3220-3228

  4. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine

    Kidney International, Vol. 96, Núm. 3, pp. 555-567

2018

  1. Phase II study of Taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor–positive advanced breast cancer

    Clinical Cancer Research, Vol. 24, Núm. 18, pp. 4380-4387

2015

  1. Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: Preclinical characterization and phase I clinical trial

    Clinical Cancer Research, Vol. 21, Núm. 1, pp. 49-59

2014

  1. The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona

    Annals of Oncology

2013

  1. Evaluation and clinical analyses of downstream targets of the akt inhibitor GDC-0068

    Clinical Cancer Research, Vol. 19, Núm. 24, pp. 6976-6986

  2. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

    Cancer Discovery, Vol. 3, Núm. 4, pp. 406-417